SL
REGN icon

Salomon & Ludwin’s Regeneron Pharmaceuticals REGN Stock Holding History

Salomon & Ludwin’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.2K Buy
58
+16
+38% +$12.2K ﹤0.01% 550
2025
Q4 		$32.1K Sell
42
-3
-7% -$2.04K ﹤0.01% 583
2025
Q3 		$27K Buy
+45
New +$25.4K ﹤0.01% 640

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Salomon & Ludwin's REGN Position: Q1 2026 in Review

Salomon & Ludwin increased its Regeneron Pharmaceuticals (REGN) stake by 38% in Q1 2026, buying an estimated $12.2K and bringing the position to 58 shares worth $44.2K. The position accounts for ﹤0.01% of the portfolio, ranked #550.

Salomon & Ludwin first reported a position in REGN in Q3 2025 and has held it in 3 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Salomon & Ludwin held 58 shares of Regeneron Pharmaceuticals worth $44.2K as of Q1 2026.
  • Salomon & Ludwin bought 16 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $12.2K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #550 holding.
  • Salomon & Ludwin first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.